IC
FHTX icon

Ikarian Capital’s Foghorn Therapeutics FHTX Stock Holding History

Ikarian Capital’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,292
Closed -$76.5K – 151
2023
Q3 		$76.5K Buy
15,292
+292
+2% +$2.25K 0.01% 127
2023
Q2 		$106K Buy
+15,000
New +$105K 0.02% 118

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's FHTX Position: Q4 2023 in Review

Ikarian Capital sold out of Foghorn Therapeutics (FHTX) in Q4 2023, closing a stake of 15,292 shares — an estimated $76.5K sold.

Ikarian Capital first reported a position in FHTX in Q2 2023 and held it in 2 quarters. The position peaked at $106K in Q2 2023. 59 funds tracked by Wall St. Rank hold FHTX as of Q4 2023.

  • Ikarian Capital reported no remaining Foghorn Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Ikarian Capital sold 15,292 Foghorn Therapeutics shares in Q4 2023, an estimated $76.5K.
  • Ikarian Capital first reported a position in Foghorn Therapeutics in Q2 2023 and held it in 2 quarters.
  • Ikarian Capital's Foghorn Therapeutics position peaked at $106K in Q2 2023.
  • 59 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2023.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.